Providing relief from treatment-resistant depression

Lophora is a drug-development start-up developing new rapid-acting drugs for central nervous system diseases including treatment-resistant depression.

Founded in 2017 Lophora has successfully finished initial characterization of our lead-candidate through PoC funding granted by the BioInovation institute and plan to begin first in human trials by 2022.

We believe we hold a unique position in the market for anti-depressant therapies of the future. The company seeks to mature lead-candidate LPH-5 through pre-clinical operations, toward IND status by the end of 2021. Given our unique technology and knowledge of the field, we are confident that we are moving ahead of a global market shift towards medically aided psychotherapy as a treatment for CNS disorders.

Interested in the antidepressant therapy of the future?

Get in Touch

Lophora is currently located at the BioInnovation Institute at COBIS Copenhagen.

Contact: bt@lophora.com

Invested in bringing relief from despair